ArticleVirchows Archiv : an international journal of pathology2026
Distinct subgroups of follicular dendritic cell sarcoma: insights from clinical, histologic and immunophenotypic characterization.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm with morphologic and phenotypic features resembling those of normal follicular dendritic cells (FDCs). FDCS has been classified into two distinct entities based on their association with Epstein-Barr Virus (EBV): classic FDCS (cFDCS) and EBV-positive inflammatory FDCS (EBV + IFDCS). Diagnosis relies on characteristic histopathology and immunohistochemistry using FDC markers and EBV in situ hybridization (EBER). This study aimed to compare the clinical presentations, histologic features, and immunoprofiles between these two entities in a Taiwanese cohort. We retrospectively reviewed histological features of in-house and consultation cases of FDCS. Immunohistochemistry with novel markers including serglycin (SRGN), FDC-secreted protein (FDCSP) was applied, together with conventional FDC markers (CD21, CD23, CD35) and EBER. Programmed death ligand-1 (PD-L1), a potential therapeutic marker, was additionally evaluated and scored. Clinical and histological parameters, inflammatory cell infiltration, mitotic rate, and PD-L1 tumor proportion score (TPS) were compared statistically. We identified 30 patients including 16 cFDCS and 14 EBV + IFDCS. The median age was 56 years old (range, 22-80), with a female preponderance in EBV + IFDCS. EBV + IFDCS occurred exclusively in extra-nodal sites, while cFDCS more commonly involved lymph nodes. EBV + IFDCS showed significantly higher PD-L1 TPS (p = 0.012), more prominent inflammatory cell infiltration (90.0% vs. 12.5%, p < 0.001) in the presence of germinal centers (50% vs. 6%, p = 0.012), and lower mitotic activity (0.5 vs. 2.5/10 HPFs, p = 0.002). We identified distinct clinical and histologic features, as well as differential PD-Ll expression between cFDCS and EBV + IFDCS, supporting their classification as separate entities. Further molecular studies are needed to investigate their pathogenesis.
Indexed as
Identifiers
42043516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.